October 21, 2019
This case study provides details on our methodology to ensure a reliable and comprehensive inventory of residual HCPs in your process intermediates and final drug substance.
GET A RELIABLE, COMPREHENSIVE INVENTORY OF RESIDUAL HCP IN YOUR PROCESS INTERMEDIATES AND FINAL DRUG SUBSTANCE
Why chose CellCarta for your Proteomic Assays
Mass spectrometry (MS) is the technology of choice for large-scale proteomic profiling and targeted quantitative biomarker analysis. CellCarta has led the way in the industrialization of MS platforms by applying them to the needs of the industry and refining MS workflows for specific clinical applications, all while applying GCLP principles and rigorous QA/QC.
